• In recent weeks, Colgate-Palmolive reported fiscal fourth quarter results that exceeded analyst expectations on both revenue and adjusted earnings per share, while continuing its 63-year streak of annual dividend increases with a US$0.52 per-share payment on February 13, 2026.
• This combination of an earnings beat, consistent dividend growth, and increased attention from institutional investors and Wall Street analysts highlights how Colgate-Palmolive’s steady consumer brands profile is drawing renewed interest.
• With this backdrop of stronger-than-expected earnings, we’ll examine how the latest results and dividend consistency shape Colgate-Palmolive’s investment narrative.

Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

Colgate-Palmolive Investment Narrative Recap

To own Colgate-Palmolive, you need to believe in the durability of its everyday brands, their ability to support steady cash generation, and disciplined capital allocation. The latest earnings beat and dividend increase support this steady profile, but do not materially change the near term risk that slower revenue growth and a high payout ratio could pressure financial flexibility if conditions worsen.

The continuation of Colgate-Palmolive’s 63-year streak of dividend increases, with a US$0.52 per share payment on February 13, 2026, is particularly relevant here. It underlines the company’s commitment to shareholder returns even as it manages softer growth and a premium valuation, which ties directly into how resilient its core oral care and home care franchises need to be to justify renewed interest from Wall Street and institutional investors.

Yet behind that long dividend record, one key risk investors should be aware of is how a high payout ratio could limit...

Colgate-Palmolive’s narrative projects $22.4 billion revenue and $3.5 billion earnings by 2028. This requires 3.8% yearly revenue growth and a roughly $0.6 billion earnings increase from $2.9 billion today.

Uncover how Colgate-Palmolive's forecasts yield a $88.89 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community value Colgate-Palmolive between US$87 and about US$124.69, showing a wide spread of expectations. When you set these views against concerns about slower revenue growth and premium pricing pressure, it becomes clear why it helps to compare several independent opinions before deciding how Colgate-Palmolive might fit in your portfolio.

Explore 4 other fair value estimates on Colgate-Palmolive - why the stock might be worth 10% less than the current price!

Build Your Own Colgate-Palmolive Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 54 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.